Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase 3 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Sarcoma 2Gastrointestinal 2Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Imatinib Mesylate × Clear all
NCT01046487 2026-03-13

PALANGI3

Centre Oscar Lambret

Phase 1 Completed
26 enrolled
DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Novartis

Phase 1 Completed
14 enrolled
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00611689 2013-02-04

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasms

NCT00026169 2013-01-10

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

National Cancer Institute (NCI)

Phase 1 Completed
69 enrolled
Tumor-Agnostic

Neoplasms

NCT01271166 2011-01-06

GlivecĀ® Plus m-FOLFOX AvastinĀ® in Advanced Colorectal Cancer

Novartis

Phase 1 Terminated
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔